BRIEF—Boehringer gets UK Innovation Passport for rare cancer med

The British business of German drugmaker Boehringer Ingelheim has received an Innovation Passport for an innovative oncology candidate, codenamed BI 907828.

The Medicines and Healthcare Products Regulatory Agency (MHRA) provides the designation as the first step in the Innovative Licensing and Access Pathway (ILAP), an accelerated regulatory route for innovative treatments where there is a significant unmet need.

Boehringer is developing the small molecule, which is designed to block the interaction between two proteins known as MDM2 and P53, to treat an aggressive and rare type of cancer that arises in fat tissues.

The therapy is being tested in the global Phase II/III Brightline-1 trial.

UK medical affairs head Douglas Clark said BI 907828 was “undergoing an extensive clinical development program across several cancer indications and is part of our robust pipeline of compounds, including cancer cell-directed and immuno-oncology investigational therapies.”